跳至主要内容
临床试验/NCT01090505
NCT01090505Unknown2 期

Phase 2 Study of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Locally Advanced

Chinese PLA General Hospital1 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2009年11月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
发起方
入组人数
160
试验地点
1
主要终点
overall survival

研究概览

简要总结

The purpose of this study is to determine whether S-1 and oxaliplatin as neoadjuvant chemotherapy may improve survival benefit compared with control.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed gastric adenocarcinoma Locally advanced disease:Clinical stage T3-4, N0-3, M0 (according to the Japanese gastric cancer classification)
  • Planning to undergo gastric cancer D2 surgery after neoadjuvant chemotherapy
  • Age:20 to 75
  • Performance status:ECOG 0-2
  • Life expectancy:Not specified
  • Hematopoietic:WBC 4,000-12,000/mm^3;Granulocyte count ≥ 2,000/mm^3;Platelet count ≥ 100,000/mm^3;Hemoglobin ≥ 9.0 g/dL;Hepatic:AST and ALT ≤ 100 U/L;Bilirubin ≤ 1.5 mg/dL
  • Adequate organ function
  • Able to swallow oral medication
  • Written informed consent

排除标准

  • Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ
  • Pregnant or breast-feeding women
  • Severe mental disease
  • Systemic administration of corticosteroids, flucytosine, phenytoin or warfarin
  • Other severe complications such as paralytic ileus, intestinal pneumonitis, pulmonary fibrosis, or ischemic heart disease
  • Myocardial infarction within six disease-free months

结局指标

主要结局

overall survival

时间窗: 5 years

次要结局

  • response rate(3 months)

研究者

发起方
Chinese PLA General Hospital
申办方类型
Other

研究点 (1)

Loading locations...

相似试验

Study of S-1 and Oxaliplatin as Neoadjuvant... | 临床试验